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INTESTINAL MICROFLORA AND IMMUNITY
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Background and aims: Perturbations in intestinal microbiota composition due to lifestyle changes may be
involved in the development of atopic diseases. We examined gut microbiota composition in early infancy
and the subsequent development of atopic manifestations and sensitisation.
Methods: The faeces of 957 infants aged 1 month and participating in the KOALA Birth Cohort Study were
analysed using quantitative real-time PCR. Information on atopic symptoms (eczema, wheeze) and potential
confounders was acquired through repeated questionnaires. Total and specific IgE were measured in venous
blood samples collected during home visits when the infant was 2 years old. During these home visits a
clinical diagnosis of atopic dermatitis was made according to the UK-Working Party criteria.
Results: The presence of Escherichia coli was associated with a higher risk of developing eczema
(ORadj = 1.87; 95% CI 1.15 to 3.04), this risk being increased with increasing numbers of E coli (pfor
trend = 0.016). Infants colonised with Clostridium difficile were at higher risk of developing eczema
(ORadj = 1.40; 95% CI 1.02 to 1.91), recurrent wheeze (ORadj = 1.75; 95% CI 1.09 to 2.80) and allergic
sensitisation (ORadj = 1.54; 95% CI 1.02 to 2.31). Furthermore, the presence of C difficile was also associated
with a higher risk of a diagnosis of atopic dermatitis during the home visit (ORadj = 1.73; 95% CI 1.08 to
2.78).
Conclusion: This study demonstrates that differences in gut microbiota composition precede the development
of atopy. Since E coli was only associated with eczema and C difficile was associated with all atopic
outcomes, the underlying mechanisms explaining these association may be different.
T
he prevalence of atopy has been increasing worldwide
during the past decades, particularly in the Western world
and amongst children.1 An enhanced T helper 2 (Th2)
immune response and the elaboration of cytokines such as
interleukin (IL)-4, IL-13 and IL-5 contribute to the induction of
atopic diseases.2 Although genetic susceptibility plays an
important role in atopy, changes in the prevalence of these
diseases have been much faster than any possible shift in
genetic constitution.3 Therefore, environmental changes asso-
ciated with a western lifestyles are thought to be involved in the
atopic epidemic. In 1989 Strachan introduced the ‘‘hygiene
hypothesis’’, which states that reduced exposure to infections
during childhood results in aberrant immune responses to
innocuous antigens later in life.4 5 However, an alternative
interpretation of this hypothesis is that perturbations in the
composition of gastrointestinal microbiota as a result of
changed lifestyles (antibiotic use, diet) in westernised countries
have disrupted the mechanisms involved in the development of
immunological tolerance.6 Regulatory antigen presenting cells
(APCreg) and regulatory T cells (Treg) play a crucial role in the
development of immunological tolerance. The maturation of
these cells might be hampered as a result of reduced exposure
to certain microbes (‘‘old friends’’) and consequently a person
may develop T helper 1 (Th1) or Th2 mediated inflammatory
disorders.7
Differences in intestinal microbiota composition have been
shown between infants in countries with high (Sweden) and
low (Estonia) allergy prevalence and also between allergic and
healthy infants.8–11 Most reports were based on small popula-
tions and although the majority of observational studies found
an association between the gut microbiota and allergy, no
protective or potentially harmful bacteria have yet been
identified.12
Further support for the role of the gut microbiota comes from
several clinical trials using probiotics in the treatment13–15 and
prevention16 17 of atopic eczema, although not all studies have
shown probiotics to be effective.18 19
In a large prospective birth cohort study in the Netherlands,
we examined the composition of the intestinal microbiota of
nearly 1000 infants aged 1 month and the subsequent
development of atopic manifestations and/or sensitisation
within the first 2 years of life.
METHODS
Subjects and study design
The KOALA Birth Cohort Study is a prospective birth cohort
study in the Netherlands aimed at identifying factors influen-
cing atopic diseases. The design of the KOALA study has been
described in detail elsewhere.20 Briefly, from October 2000 until
December 2002 we recruited pregnant women with diverse
lifestyles at 34 weeks of gestation. Pregnant women with a
conventional lifestyle (n = 2343) were recruited from an
ongoing prospective cohort study on pregnancy-related pelvic
girdle pain in the Netherlands.21 Additionally, pregnant women
with alternative lifestyles (n = 491) as regards child rearing
practices, dietary habits (organic, vegetarian), vaccination
schemes and/or the restricted use of medication, were recruited
through organic food shops, anthroposophic doctors and
midwives, Steiner schools and magazines.
During pregnancy and early childhood, data on perinatal
determinants of the child’s health as well as on hygiene,
infections, nutrition, child rearing, other lifestyle characteristics
Abbreviations: CFU, colony forming units; Ig, immunoglobulin; IL,
interleukin; OR, odds ratio; Th1, Th2, T helper 1, 2; Treg, regulatory T cell;
UK-WP, UK-Working Party
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and atopic manifestations were collected for all members of the
cohort by repeated questionnaires at 34 weeks of gestation and
at 3, 7, 12 and 24 months post partum.
Participants (with both conventional and alternative life-
styles) recruited from January 2002 onwards were asked to
sample the infant’s faeces at the age of 1 month post partum
(n = 1176). Subjects received a faeces tube with a spoon
attached to the lid (Sarstedt, Nu¨mbrecht, Germany), together
with a sanitary napkin, an instruction form and a brief
questionnaire (faeces questionnaire). Parents placed a sanitary
napkin in the diaper (to prevent absorption of the faeces by the
diaper), collected the faeces out of the napkin into the
collection tube and sent it immediately to our laboratory by
post. Transport time was minimised by asking the parents to
collect the faeces on a Monday, Tuesday or Wednesday, so that
the samples did not remain in the mail service over the
weekend.
The study cohort comprised 957 infants after exclusion of
premature infants, infants who received antimicrobial agents
during their first month of life, infants from whom insufficient
amounts of faeces (,1 g) were collected, infants whose faeces
were not collected between 3 and 6 weeks of age and infants for
whom the faeces questionnaire was missing.
Home visits were made by trained nurses when the infant
was 2 years of age (n = 607). During these visits a clinical
diagnosis of atopic dermatitis was determined using the UK-
Working Party (UK-WP) criteria.22–24 Venous blood was also
collected from the infants in order to determine total (n = 590)
and specific (n = 583) serum immunoglobulin (Ig)E.
The KOALA study was approved by the Ethics Committee of
the University Hospital of Maastricht and all parents signed
informed consent for the study.
DNA purification from faeces
At the laboratory faecal samples were diluted tenfold in
peptone-water (Oxoid CM0009) containing 20% v/v glycerol
(Merck, Darmstadt, Germany) and stored at 220 C˚ until
analysis. For DNA isolation, 0.2 ml of the diluted faeces was
added to a 2 ml vial containing approximately 300 mg glass
beads (diameter 0.1 mm) and 1.4 ml of ASL-buffer from the
QIAamp DNA Stool Mini Kit (Qiagen, Hilden, Germany) and
the samples disrupted in a mini-bead beater (Biospec Products,
Bartlesville, OK) at 5000 rpm for 3 min. Subsequently, bacterial
DNA was isolated from the samples using the QIAamp DNA
Stool Mini Kit according to the instructions of the manufac-
turer. The DNA was eluted in a final volume of 200 ml.
Microbial analysis of faecal samples
Faecal samples were subjected to real-time PCR for counting of
Bifidobacterium spp, Escherichia coli, Clostridium difficile, Bacteroides
fragilis group, Lactobacillus spp, and total bacterial counts as
described previously25 (primers and probes are listed in table 1).
The log10 colony forming units (CFU) per gram of the bacterial
groups and species were calculated for each stool sample from
the threshold cycle values using the constructed standard
curves. The prevalence of colonisation was expressed as the
percentage of infants colonised with a specific bacterial group
or species.
Determination of total and specific IgE
Blood samples collected during home visits when the infant
was 2 years of age were analysed for total and specific serum
IgE by Sanquin Research (Amsterdam). For total IgE levels,
samples were analysed as described earlier.33 34 A sandwich RIA
was used for values ,150 IU/ml 34 and a competitive RIA for
values .150 IU/ml.33 The detection limit for total serum IgE
was ,0.5 IU/ml. Blood samples were analysed for specific IgE
against hen’s egg, cow’s milk, peanuts, birch pollen, grass
pollen, cat, dog and house dust mite using RAST as described
previously.33 Calculation was performed by means of a standard
curve that was obtained by RAST with a dilution series of a
chimeric monoclonal IgE antibody against the major house
dust mite allergen Der-p2 and Sepharose-coupled recombinant
Der-p2.35 A RAST value of .0.3 IU/ml was regarded as positive.
Definition of atopic manifestations and sensitisation
Our definitions of eczema and wheeze were based on questions
adapted from the ISAAC questionnaires.36 In the 7, 12 and
24 months’ postpartum questionnaires, parents were asked:
‘‘has your child ever had an itchy rash that came and went over
the past months?’’. If this question was answered affirmatively,
infants were defined as having developed eczema in the first
2 years of life. Infants for whom only diaper rash, rash around
the eyes and/or scalp scaling was reported were not regarded as
having developed eczema.
‘‘Recurrent wheezing’’ was defined as the reported presence
of wheezing with at least four attacks between 0 and 7 months
mentioned in the 7 months’ postpartum questionnaire and/or
between 7 and 12 months of life mentioned in the 12 months’
postpartum questionnaire and/or between 13 and 24 months
mentioned in the 24 months’ postpartum questionnaire.
Besides the eczema reported by the parents, a diagnosis of
atopic dermatitis could be made using the UK-WP criteria for
those infants visited at home.22–24 Briefly, the presence of atopic
dermatitis was determined according to four clinical symptoms:
(i) the presence of an itchy rash, (ii) a history of flexural
dermatitis, (iii) visible flexural dermatitis, and (iv) onset before
the age of 2 years. In this study, infants with a probability of
atopic dermatitis of .0.9 were considered to have atopic
dermatitis.
Infants with specific serum IgE levels .0.3 IU/ml against one
or more of the tested food or inhalant allergens were considered
to be sensitised.
Definition of potential confounders
The following variables were included as potential confounders:
subcohort (conventional; alternative), parental atopic history
defined as self-reported doctor-diagnosed eczema, hay fever,
asthma, and pet and/or house dust mite allergy (none; at least
one parent), siblings with an atopic history defined as parent-
reported doctor-diagnosed food allergy, eczema, hay fever,
asthma, and pet and/or house dust mite allergy (no siblings;>1
sibling, none atopic; or >1 sibling, at least one atopic), age at
collection of faecal sample (age in days) and infant’s gender
(boy; girl). Maternal probiotic use during the last month of
pregnancy (never/sporadic; several times a month; several
times a week; daily), place and mode of delivery (vaginal
delivery at home; vaginal delivery in hospital; artificial delivery
in hospital; or caesarean section in hospital), type of infant
feeding during the first month (exclusively breast-fed; exclu-
sively formula-fed or a combination) were included as a
separate set of confounders. These latter variables may be more
distal determinants in the association between the gut
microbiota and atopic manifestations instead of true confoun-
ders, and adjusted analyses were therefore performed with and
without adjustment for these variables.
Statistical analyses
Logistic regression analyses were used to test for (unadjusted)
associations between colonisation with the gut bacteria
(colonised or uncolonised) under study and the development
of atopic outcomes (eczema (reported by parent), atopic
dermatitis (UK-WP criteria), recurrent wheeze and/or atopic
sensitisation). Adjusted associations were tested by incorporating
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the potential confounders into the logistic regression models. Two
different sets of confounders were used. The first set included the
variables subcohort, parental and sibling atopic history, age at
collection of the faecal sample and infant’s gender, and the second
set included these variables as well as maternal probiotic use
during pregnancy, place and mode of delivery and type of infant
feeding. Since almost all infants were colonised, the association
between colonisation with bifidobacteria and atopic outcomes
was analysed as ‘‘low’’ (,10.68 log10 CFU/g) versus ‘‘high’’
(>10.68 log10 CFU/g) bifidobacterial counts; the few uncolonised
infants (n = 12) were added to the low counts group. The cut-off
point of 10.68 log10 CFU/g was chosen to create two equal groups.
Logistic regression analyses were also used to test for
associations between the concentration (counts) of gut bacteria
and atopic outcomes. We additionally adjusted for total
bacterial counts to account for differences in the consistency
of faecal samples in the analyses on bacterial numbers, in
addition to the confounders described above. To test for trend,
bacterial counts were categorised (uncolonised infants were
used as the reference category and the remaining colonised
infants were accommodated in two (C difficile, lactobacilli) or
three equal groups (bifidobacteria, E coli, B fragilis group)).
Linear regression analyses were used to test for associations
between the gut bacteria under study and total serum IgE
levels, controlling for the same confounders mentioned above.
Since separate analyses of the conventional and alternative
subcohorts showed that the key findings were similar within
these two subcohorts, in the final analyses we combined the
two groups adjusting for ‘‘subcohort’’.
To examine the possibility of selection bias in those infants
visited at home, we performed non-response analyses. Using
logistic regression analyses, infants visited at home (n = 607)
were compared with infants not visited at home (n = 305)
regarding gut microbiota composition and the prevalence of
eczema and recurrent wheeze.
RESULTS
Of the 957 infants participating in this study, almost all were
colonised with bifidobacteria (98.7%) at the age of 1 month
(table 2). Most of the infants were also colonised with E coli
(88.6%) and members of the B fragilis group (81.6%), whereas
colonisation with lactobacilli (32.2%) and C difficile (25.1%) was
less common. Bifidobacteria were detected in the highest
numbers, followed by E coli and B fragilis group species.
More than half of the infants had at least one parent with a
positive history of doctor-diagnosed atopic manifestations
(table 2). Almost one third of the infants who had older
siblings, had an atopic sibling. Over 30% of the infants had
developed eczema at the age of 2 years and recurrent wheeze
was reported in approximately 10%. Over a quarter of the
infants had circulating IgE antibodies (.0.3 IU/ml) in their
blood against one or more of the food and/or inhalant allergens
and thus were regarded as sensitised.
Non-response analyses showed that there were no differ-
ences in the composition of gut microbiota or in the prevalence
of eczema and recurrent wheeze between infants who were
visited at home and those who were not (data not shown).
Table 3 shows the adjusted association between colonisation
with the gut bacteria under study at the age of 1 month and the
development of atopic manifestations within the first 2 years of
life. The risk of eczema was significantly higher in infants
colonised with E coli (adjusted odds ratio (ORadj) = 1.87; 95% CI
1.15 to 3.04) compared with infants not colonised with E coli at
the age of 1 month. For those infants visited at home, we were
also able to define atopic dermatitis according to the UK-WP
criteria. However a higher risk for infants colonised with E coli
was not found when atopic dermatitis was defined according to
these criteria (ORadj = 1.02; 95% CI 0.49 to 2.10).
Infants colonised with C difficile were also at higher risk of
eczema (ORadj = 1.40; 95% CI 1.02 to 1.91) compared with
uncolonised infants. This association was even stronger for
atopic dermatitis according to the UK-WP criteria
(ORadj = 1.73; 95% CI 1.08 to 2.78). Colonisation with C difficile
was furthermore associated with a higher risk of developing
recurrent wheeze (ORadj = 1.75; 95% CI 1.09 to 2.80) and atopic
sensitisation (ORadj = 1.54; 95% CI 1.02 to 2.31).
Colonisation with bifidobacteria, B fragilis group species and
lactobacilli was not associated with any of the atopic outcomes.
Results of the unadjusted analyses (data not shown) were
comparable with the adjusted analyses. Also, the results of the
analyses in which we additionally adjusted for maternal
probiotic use during pregnancy, place and mode of delivery
and type of infant feeding (data not shown) were comparable
with the results presented in table 3.
We subsequently analysed the association between the
counts of the bacteria under study and the atopic outcomes.
Both unadjusted (data not shown) and adjusted analysis
revealed that the risk of developing eczema increased with
increasing numbers of E coli in the faecal samples (pfor
trend = 0.016) (fig 1). Infants with high E coli counts in their
stools had a twofold higher risk of developing eczema compared
with uncolonised infants. Again this association was not found
when atopic dermatitis was defined according to the UK-WP
criteria. The association between C difficile colonisation and
Table 1 Primers and probes used in this study
Target organisms (amplicon size) Primer/probe Sequence (59-39) Tm ( C˚) Reference
Bifidobacterium spp (126 bp). Forward primer GCGTGCTTAACACATGCAAGTC 59 Penders et al26
Reverse primer CACCCGTTTCCAGGAGCTATT 59 Penders et al26
Probe TCACGCATTACTCACCCGTTCGCC 70 Penders et al26
Escherichia coli (96 bp) Forward primer CATGCCGCGTGTATGAAGAA 59 Huijsdens et al27
Reverse primer CGGGTAACGTCAATGAGCAAA 59 Huijsdens et al27
Probe TATTAACTTTACTCCCTTCCTCCCCGCTGAA 68 Huijsdens et al27
Clostridium difficile (114 bp) Forward primer TTGAGCGATTTACTTCGGTAAAGA 58 Penders et al26
Reverse primer TGTACTGGCTCACCTTTGATATTCA 59 Penders et al26
Probe CCACGCGTTACTCACCCGTCCG 69 Penders et al26
Bacteroides fragilis group (92 bp) Forward primer CGGAGGATCCGAGCGTTA 58 Penders et al25
Reverse primer CCGCAAACTTTCACAACTGACTTA 59 Liu et al28
Probe CGCTCCCTTTAAACCCAATAAATCCGG 68 Penders et al25
Lactobacillus spp (341 bp) Forward primer AGCAGTAGGGAATCTTCCA 59 Walter et al,29 Rinttila et al30
Reverse primer CACCGCTACACATGGAG 59 Rinttila et al,30 Heilig et al31
Total count (467 bp) Forward primer TCCTACGGGAGGCAGCAGT 59 Nadkarni et al32
Reverse primer GGACTACCAGGGTATCTAATCCTGTT 58 Nadkarni et al32
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eczema, atopic dermatitis, recurrent wheeze and atopic
sensitisation was not influenced by the concentration of this
bacterium in the faecal samples. Furthermore, counts of
bifidobacteria, B fragilis group species and lactobacilli were
not associated with atopic disease manifestation or sensitisa-
tion.
Total serum IgE level at the age of 2 years was not associated
with colonisation rates or counts of gut bacteria.
DISCUSSION
This prospective study demonstrates that differences in gut
microbiota composition in early infancy are associated with the
subsequent development of atopic disease manifestation and
sensitisation. The presence of E coli was associated with a
higher risk of developing eczema, this risk being increased with
increasing numbers of E coli. However, this association was not
found when atopic dermatitis was defined according to the UK-
WP criteria. Colonisation with C difficile in early infancy was
associated with an increased risk of all atopic outcomes
(eczema, atopic dermatitis, recurrent wheeze and atopic
sensitisation), independent of the concentration of this
bacterium.
This is the first large-scale prospective study on gut
microbiota composition in relation to atopic manifestations.
Although previous epidemiological studies were very informative
and were the first to suggest a potential role of the gut microbiota
in the aetiology of atopic diseases, they were often based on small
populations and were not able to adjust for potential confounders.
Furthermore, only two previous studies9 11 were prospective and
therefore able to determine if differences in the gut microbiota
precede the development of atopic symptoms. Another strength of
our study is the molecular techniques used, which overcome many
of the problems associated with traditional bacteriological culture.
Analyses of the gut microbiota using bacteriological culture are
biased, since many selective culture media are not absolutely
selective. Furthermore, these media do not equally support the
growth of the different species comprising a population, and not
all bacteria are cultivatable.37 38 The real-time PCR assays used in
the present study are a quantitative culture-independent approach
suitable for high-throughput analyses of both fresh and frozen
samples.
At present, faeces is the only realistic sample available in
large non-invasive epidemiological studies on the gut micro-
biota. However, a limitation of using faecal samples is that the
bacterial composition in the lumen does not reflect the
composition of bacteria adhering to the mucosa, and further-
more the composition of bacteria differs throughout the
intestinal tract.39 Nevertheless, it can be assumed that although
the proportions and activities of the microbiota change with
passage through the intestinal tract, most viable and non-viable
Table 2 Characteristics of the participants in this study
Conventional subcohort,
n = 652*
Alternative subcohort,
n = 305*
Prevalence of colonisation with intestinal bacteria, %
Bifidobacteria 98.3 99.7
Escherichia coli 89.5 86.6
Clostridium difficile 24.7 25.9
Bacteroides fragilis group 83.0 78.7
Lactobacilli 33.1 30.2
Counts of intestinal bacteria (log10 CFU/g), median (range)
Bifidobacteria 10.71 (6.84–11.56) 10.68 (6.85–11.49)
Escherichia coli 9.45 (5.91–10.79) 9.12 (5.92–10.62)
Clostridium difficile 5.12 (2.70–8.41) 5.70 (2.85–8.81)
Bacteroides fragilis group 9.40 (5.74–10.36) 9.07 (5.79–10.33)
Lactobacilli 8.70 (7.92–10.73) 8.58 (7.95–10.33)
Total counts 11.15 (9.43–12.14) 11.08 (9.58–11.98)
Age at collection of faecal sample (days), mean (SD) 31.60 (3.28) 31.75 (3.31)
Parental history of atopic manifestations, %
At least one parent with atopy 54.8 51.8
Sibling history of atopic manifestations, %
No siblings 43.7 32.8
>1 siblings, non-atopic 40.5 46.2
>1 siblings, at least one atopic 15.6 21.0
Sex of infant (boys, percentage) 49.4 53.4
Maternal probiotic use, %
Never/sporadic 78.5 79.9
Several times a month 9.5 9.8
Several times a week 6.7 6.2
Daily 1.4 3.0
Place and mode of delivery, %
Natural delivery at home 44.0 53.8
Natural delivery in hospital 34.8 29.2
Artificial delivery in hospital` 7.5 6.9
Caesarean section in hospital 10.7 9.5
Type of infant feeding, %
Exclusively breast-fed 58.3 87.9
Exclusively formula-fed 29.4 7.2
Combination 12.0 4.9
Infants with atopic outcome at age 2 years, %
Eczema 32.8 31.7
Recurrent wheeze 12.8 6.3
Sensitisation1 29.9 25.0
Total IgE, median (range) 10.0 ( 0.5–5300.0) 16.5 ( 0.5–3700.0)
*Overall numbers are not always 652 for the conventional subcohort and 305 for the alternative subcohort due to missing bacterial count data or outcome data;
consumed during the last month of pregnancy; `forceps or vacuum extraction; 1only available for those infants visited at home, total numbers are 391 for conventional
subcohort and 192 for alternative subcohort; only available for those infants visited at home, total numbers are 396 for conventional subcohort and 194 for alternative
subcohort.
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intestinal bacteria will still be detectable in the faeces by
molecular methods.40 A drawback of this study is the time
between collection of the samples by the parents and processing
of the samples in the laboratory, which was 1 day for most
samples. Ott and colleagues41 demonstrated that the total
amount of bacterial DNA as well as the diversity of the
microbiota significantly decreased over such a time span.
However, they also showed that the similarity (determined by
DGGE) of faecal samples processed immediately and processed
after 24 h remained high. This means that the dominant
microbiota appears to be relatively stable. Furthermore, the aim
of the present population-based study was to examine
differences in gut microbiota composition between subjects. It
is not likely that the possible change in composition of the
samples during transportation was different for infants who
developed atopic manifestations later on in life and infants who
did not.
In the present study, only one faecal sample per infant was
collected at the age of 1 month post partum. There are several
reasons why we chose to collect faeces at this age. First, as the
gut microbiota is thought to drive the postnatal development of
the immune system,12 the first months of life seem to be of
major importance. Second, at the age of 1 month colonisation is
complete and although the composition may fluctuate, large
shifts in the composition do not occur until weaning.42 Finally,
as we wanted to exclude the chance of reverse causation, the
gut microbiota composition had to be analysed prior to the
manifestation of atopic symptoms.
Since manifestation of atopic symptoms and sensitisation to
allergens do not always occur together (sensitised infants do
not always show symptoms and infants with symptoms are not
always sensitised),43 we chose to report the manifestation of
atopic symptoms and sensitisation as separate outcome
parameters. As a consequence we decided to use the term
eczema instead of atopic eczema or atopic dermatitis. However,
we did use the term atopic dermatitis for those infants visited at
home who fulfilled the UK-WP criteria, since Williams and
colleagues when introducing these criteria originally used the
term atopic dermatitis.22
The positive association we found between E coli and eczema
is difficult to compare with previous reports, since several of
these studies did not determine E coli9 or measured this
bacterium as part of total coliforms,8 enterobacteriaceae10 or
Gram-negative rods.11
In contrast to the association between E coli and eczema
(based on parents’ reports in questionnaires), we did not find
an association between E coli and atopic dermatitis based on the
UK-WP criteria. Selection bias could not explain this difference
since non-response analyses showed that the gut microbiota
and the prevalence of eczema and recurrent wheeze was similar
for those infants who were visited at home and those who were
not. The percentage of infants with atopic dermatitis according
to the UK-WP criteria is much lower than the percentage of
infants with eczema reported by parents. This can be explained
by the fact that eczema reported by parents is based upon the
presence of this condition at any time during the infants’ first
2 years of life, whereas many of these infants are probably in
remission or have already outgrown this condition at time of
the home visit. Therefore, it is possible that E coli is only
associated with a milder eczematous condition that has already
disappeared by the time of the home visit. Another explanation
for these discrepant findings is that the UK-WP criteria
included specific predilection sites of atopic dermatitis (flexural
involvement),22–24 whereas the questionnaire data were based
on the presence of an itchy rash anywhere (except diaper rash,
rash around the eyes and scalp scaling). The increased risk of
Table 3 The adjusted association between colonisation with gut bacteria at 1 month of age and atopic sensitisation and atopic
disease manifestation at 2 years of age (n = 957)
Intestinal
bacteria
Eczema Recurrent wheeze Atopic dermatitis (UK-WP)` Sensitisation1
Prevalence (n/N) ORadj (95% CI)** Prevalence (n/N) ORadj (95% CI)** Prevalence (n/N) ORadj (95% CI)** Prevalence (n/N) ORadj (95% CI)**
Bifidobacteria
Low 32.4% (148/457) 1.0 9.4% (41/434) 1.0 17.9% (54/302) 1.0 26.5% (76/287) 1.0
High 32.5% (156/480) 1.02 (0.77 to 1.35) 11.8% (55/466) 1.32 (0.85 to 2.06) 14.4% (44/305) 0.79 (0.51 to 1.23) 30.1% (89/296) 1.23 (0.85 to 1.77)
E coli
No 22.2% (24/108) 1.0 5.8% (6/104) 1.0 15.9% (10/63) 1.0 30.6% (19/62) 1.0
Yes 33.8% (279/826) 1.87 (1.15 to 3.04)* 11.1% (88/793) 1.92 (0.80 to 4.59) 16.2% (88/542) 1.02 (0.49 to 2.10) 28.1% (146/519) 0.86 (0.48 to 1.54)
C difficile
No 30.3% (213/702) 1.0 9.4% (63/671) 1.0 14.1% (64/454) 1.0 26.1% (115/440) 1.0
Yes 38.7% (91/235) 1.40 (1.02 to 1.91)* 14.4% (33/229) 1.75 (1.09 to 2.80)* 22.2% (34/153) 1.73 (1.08 to 2.78)* 35.0% (50/143) 1.54 (1.02 to 2.31)*
B fragilis group
No 32.0% (55/172) 1.0 9.0% (15/166) 1.0 12.5% (14/112) 1.0 29.9% (32/107) 1.0
Yes 32.5% (249/765) 1.02 (0.71 to 1.47) 11.0% (81/734) 1.20 (0.66 to 2.18) 17.0% (84/495) 1.41 (0.76 to 2.60) 27.9% (133/476) 0.90 (0.57 to 1.43)
Lactobacilli
No 31.2% (199/637) 1.0 10.3% (63/613) 1.0 15.7% (64/408) 1.0 28.0% (110/393) 1.0
Yes 35.0% (105/300) 1.23 (0.91 to 1.65) 11.5% (33/287) 1.22 (0.77 to 1.93) 17.1% (34/199) 1.14 (0.72 to 1.81) 28.9% (55/190) 1.04 (0.71 to 1.53)
Based on parents’ reports in 7, 12 and/or 24 months’ questionnaires; `as determined by trained nurses during home visits; 1specific IgE antibodies to at least one allergen (cow’s milk, hen’s egg, peanut, birch
pollen, grass pollen, cat, dog, house dust mite); numbers in table do not always add up to 957 due to missing bacterial count data or outcome data; **from logistic regression analysis: adjusted for subcohort,
parental history of atopy, sibling history of atopy, age at collection of faecal sample and infant’s gender; colonisation with bifidobacteria in association with atopic sensitisation and disease manifestation presented
as low (,10.68 log10 CFU/g) versus high (>10.68 log10 CFU/g) counts since almost all infants were colonised; uncolonised infants (n = 12) were added to the low counts group.
*p,0.05 two-sided.
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Figure 1 Adjusted association between numbers of Escherichia coli
(log10 CFU/g faeces) in faecal samples of 1 month old infants and the
development of eczema in the first 2 years of life (adjusted for subcohort,
parental history of atopy, sibling history of atopy, age at collection of faecal
sample, infant’s gender and total bacterial count). Dots represent the odds
ratios, bars represent the 95% confidence intervals. Low:
,8.86 log10 CFU; middle: 8.86 to 9.75 log10 CFU; high:
.9.75 log10 CFU.
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eczema in infants colonised with E coli may therefore also be
limited to eczema other than at the specific predilection sites for
atopic eczema/dermatitis and thus may be non-atopic. This idea
is supported by the fact that we also found no association
between E coli and sensitisation.
In contrast, C difficile appears to be associated with a higher
risk of atopic eczema since a positive association was also found
for atopic dermatitis according to UK-WP criteria and for
sensitisation. Our findings of an association between C difficile
and atopy are in agreement with several previous studies. In a
study on microflora-associated characteristics, allergic infants
had higher levels of i-caproic acid in their stools compared with
non-allergic infants. This short chain fatty acid is suggested to
indicate the presence of C difficile.44 Two studies used IgG
serology against C difficile. Woodcock and colleagues found
increased specific IgG against C difficile in sensitised wheezy
infants compared with non-sensitised non-wheezy infants.45
Linneberg and colleagues found a positive association between
IgG seropositivity against C difficile and both allergic rhinitis and
sensitisation.46
Furthermore, several studies found an association between
high numbers of the genus Clostridium and atopic dermatitis
and/or sensitisation,9 11 47 although others did not find such an
association.10 48 The genus Clostridium is a very heterogeneous
group comprising several different clusters.49 It seems therefore
unlikely that the members of such a phyologenetically diverse
genus like Clostridium all have the same effect on the human
host. It is more likely that certain species (such as C difficile) or a
certain cluster of species within this genus is responsible for the
increased risk of developing atopic manifestations.
In contrast to several other studies,8–11 47 we did not find a
negative association between allergies and bifidobacteria. A
possible explanation is the lack of contrast in our study with
respect to bifidobacterial counts, because almost all infants
were colonised with high numbers of bifidobacteria. This is
probably the consequence of the very young age of our
population, an age at which bifidobacteria are known to
dominate the gut microbiota.50
Altogether our results support a role of the gut microbiota in
the aetiology of atopic diseases. There are several hypotheses by
which the associations we found between C difficile and E coli
and atopic manifestations could be explained. First of all it
should be noted that many of the bacteria in the gut are still
unknown; differences in E coli and C difficile colonisation found
in our study could therefore also reflect differences in other
unknown bacteria.9
The presence of E coli and C difficile could be associated with a
decrease in other (unknown) beneficial bacteria. This could
result in reduced induction of Treg cells by these beneficial
bacteria leading to immune dysregulation. In the absence of
optimal levels of immune regulation, an individual may develop
a Th1 (such as Crohn’s disease or autoimmunity) or Th2 (such
as atopic diseases) mediated inflammatory disorder depending
on their own Th1/Th2 bias, immunological history and genetic
background.7 Secondly, E coli and C difficile could have a direct
effect on the production of cytokines by antigen-presenting
cells, thereby affecting the differentiation of T cells.51 Another
hypothesis is that E coli and/or C difficile increase the intestinal
permeability (for instance by the production of toxins). This
increased permeability of the intestinal barrier could facilitate
the penetration of innocuous antigens and subsequent sensi-
tisation.46 Indeed it has been shown that C difficile toxins A and
B compromise the intestinal cell barrier.52 53 Furthermore,
increased intestinal permeability has been described in patients
with food allergies, eczema and asthma compared with healthy
subjects.54–57 Finally, it has also been suggested that infants
susceptible to the development of allergies are also susceptible
to aberrant colonisation of the gut. However, this explanation
seems less likely since we have controlled for familial history of
atopy. Additionally, the fact that differences in the gut
microbiota are already present at such a young age preceding
atopic symptoms makes this hypothesis less likely.
The consistent findings of a positive association between C
difficile and all atopic symptoms as well as sensitisation
strengthen the probability of a causal relationship between
the gut microbiota and atopy, and support the potential role of
probiotics in the prevention and treatment of these diseases.
We have previously examined the external factors influencing
the composition of the gut microbiota in early infancy.25
Caesarean section, antibiotic therapy, hospitalisation and
formula feeding all caused perturbations in the gut microbiota
by increasing colonisation rates and counts of E coli and C
difficile and/or by decreasing numbers of bifidobacteria. In
particular, when the gut microbiota is disrupted by one or more
of these external factors, probiotics may be effective in the
treatment or prevention of atopic diseases.
Perturbations in the gut microbiota may also be related to
other atopic outcomes which manifest at older ages such as
asthma, rhinoconjunctivitis and persistent food allergies; long
term follow-up of cohort studies is necessary to examine
whether perturbations are also related to these outcomes.
In conclusion, we demonstrated that differences in the gut
microbiota composition precede the manifestation of atopic
symptoms and atopic sensitisation. In particular, C difficile was
associated with all atopic symptoms and sensitisation, whereas
E coli appeared to be only associated with (non-atopic) eczema.
Different immunological mechanisms may underlie the effects
of E coli and C difficile. This calls for further research on the
mechanisms by which intestinal microbes interfere with our
(gastrointestinal) immune system.
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